# Pizarra — PT-pseudo_376de00c8131 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_376de00c8131
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 52-year-old male
  - PSA: 8.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.09 ng/mL²
  - PSA velocity: 0.65 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 98.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.61692226 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: Latex
  - Additional notes: PSA 8.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 98 mL. csPCa 0.62.

Vitals: weight 109 kg, height 192 cm, BMI 29.6, BP 122/78 mmHg, HR 68 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2013).

Chief complaint: Persistent elevation in prostate-specific antigen accompanied by a newly identified PI-RADS 4 lesion on magnetic resonance imaging, documented after a prior negative biopsy.

History: At 52 years of age, he works as a retired secondary school teacher. Initial evaluation in late 2022 focused on a prostate-specific antigen level of 7.1 ng/mL, which led to a systematic biopsy yielding entirely benign results. He is married and maintains an independent household, with his adult son living close by. Physical activity includes cycling roughly 20 kilometres two times each week, while alcohol intake averages 10 units weekly. Lower urinary tract symptoms remain negligible, reflected by an International Prostate Symptom Score of 2 out of 35. He reports no haematuria, pelvic discomfort, or systemic complaints. A 13 pack-year smoking history was concluded in 2013, and he has no known drug allergies beyond latex. Recent routine dental visits continue, and he relies on large-print materials for correspondence due to mild visual impairment. No other significant surgical history or comorbidities are noted, and he takes no active medications.

Physical examination: DRE — texture: smooth and firm; mobility: normal; asymmetry: absent. The prostate presents as symmetrically enlarged without palpable nodules. General inspection reveals a well-nourished individual ambulating independently. Vital signs remain stable, and there is no evidence of abdominal masses or peripheral lymphadenopathy.

Patient info: retired secondary school teacher; Married; Lives alone; adult son nearby.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 10 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.68 +/- 0.20   (95% CI 0.25-0.97)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 4.8 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=8.8, age=52.0, psad=0.09, dre_ord=0.0, vol=98.0, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical recommender only used the visible panel data (PI-RADS 4, PSA 8.8, PSA density 0.09, age 52, volume 98.0 mL, prior negative biopsy) and could not account for the PSA velocity (0.65 ng/mL/yr), the csPCa predicted probability (0.61692226), or the specific context of the guideline criterion (prior negative biopsy).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a 68% probability, but the guideline criterion is specific: "do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed." The prior failed to weigh the specific context of the prior negative biopsy against the current PI-RADS 4 finding, which is central to the protocol. The prior's wide error bar suggests it cannot distinguish between the clinical scenarios where biopsy is warranted versus where active surveillance is appropriate.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding the prior negative biopsy
laboratory panel - full panel
family-history of prostate cancer (anamnesis)

GUIDELINE ANCHOR
The guideline constrains the decision by stating that a repeat biopsy is indicated when an mpMRI shows a PI-RADS 4-5 lesion, and it suggests that a stable MRI (PI-RADS 1-3) does not make repeat biopsy superfluous.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_376de00c8131", "radiology_report": "Subject: Multiparametric MRI of the Prostate | Date: 20 February 2025 | Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)\nClinical context: Elevated prostate-specific antigen (8.8 ng/mL) with re-evaluation after a previously negative biopsy.\nFINDINGS:\nGlandular volume registers at 98.0 mL. T2-weighted sequences highlight a 18 mm focal hypointense area within the peripheral zone of the right mid-gland. Diffusion-weighted imaging exhibits pronounced restricted diffusion, mirrored by corresponding low signal intensity on the apparent diffusion coefficient map. Dynamic contrast-enhanced sequences demonstrate early, focal enhancement confined to the lesion. Seminal vesicles appear normal, with no signs of extracapsular extension or suspicious pelvic lymphadenopathy.\nIMPRESSION:\nPI-RADS 4 lesion in the right mid-gland peripheral zone, measuring approximately 18 mm. PSAD 0.09 ng/mL/mL. csPCa predicted probability 0.61692226."}
get_psa_trend
{"case_id": "PT-pseudo_376de00c8131", "psa_trend": [{"date": "Nov 2022", "val": 7.3}, {"date": "Aug 2023", "val": 7.3}, {"date": "May 2024", "val": 6.5}, {"date": "Feb 2025", "val": 8.8}]}
get_previous_notes
{"case_id": "PT-pseudo_376de00c8131", "previous_notes": [{"date": "07 Sep 2023", "author": "Dr. N. Kuiper (GP)", "text": "07 Sep 2023 - Dr. N. Kuiper (GP): Routine screening captured a PSA level of 6.4 ng/mL, marking a modest decrease from the 7.1 ng/mL recorded in late 2022. Owing to the sustained elevation beyond standard limits and his age, his records were submitted to the urology outpatient clinic to facilitate further diagnostic evaluation and potential imaging."}, {"date": "05 Mar 2024", "author": "Dr. N. Kuiper (GP)", "text": "05 Mar 2024 - Dr. N. Kuiper (GP): Serial testing indicates a gradual PSA ascent, currently at 7.0 ng/mL. Having finished his initial urological workup, he returned for review. In light of the persistent biochemical markers and the requirement for structured surveillance, a follow-up appointment has been arranged to evaluate the most recent imaging and clinical findings."}]}
get_lab_results
{"case_id": "PT-pseudo_376de00c8131", "laboratory_results": [{"name": "PSA", "val": "8.8 ng/mL", "date": "29 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.72 ng/mL", "date": "29 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "20%", "date": "29 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "15.6 g/dL", "date": "29 Jan 2025", "flag": ""}, {"name": "WBC", "val": "7.8 x10^9/L", "date": "29 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "171 x10^9/L", "date": "29 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "83 umol/L", "date": "29 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "29 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "11.7 nmol/L", "date": "29 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "67 U/L", "date": "29 Jan 2025", "flag": ""}, {"name": "LDH", "val": "192 U/L", "date": "29 Jan 2025", "flag": ""}]}

NOT RETRIEVED
The family-history of prostate cancer anamnesis was not retrieved, which is not critical for the decision based on the retrieved evidence.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 4 lesion in the right mid-gland peripheral zone, measuring approximately 18 mm.
- PSA trend: Rising from 6.5 ng/mL (May 2024) to 8.8 ng/mL (Feb 2025), showing an upward trajectory.
- Guideline criterion: Re-biopsy is indicated for a PI-RADS 4-5 lesion following a prior negative biopsy.

AGAINST sampling this patient now:
- Previous notes: Prior biopsy was negative.
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly supports proceeding with a targeted biopsy due to the presence of a PI-RADS 4 lesion and the patient's history of a prior negative biopsy, aligning with the EXPERT-PROTOCOL criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is strongly supported by the EXPERT-PROTOCOL criterion, which mandates re-biopsy for a PI-RADS 4-5 lesion following a prior negative biopsy. This is driven by the PI-RADS 4 finding in the right mid-gland peripheral zone and the history of a prior negative biopsy. The PSA trend, rising from 6.5 ng/mL to 8.8 ng/mL, further supports the need for further investigation. The statistical prior suggested biopsy, and the retrieved MRI report confirmed the presence of a PI-RADS 4 lesion, leading to convergence.

Variables that carried weight: bx=decisive, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
